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methods. 1%/1mm and local normalization is able to detect 
all type of errors (1%/1mm with global normalization is not 
able to detect the systematic shift of 2,5 mm), but it could 
overestimates some errors that have not clinical impact. In 
the table, we reported the results of sensitivity and 
specificity of PF to detect clinically relevant errors.  
 
 
 
Conclusion: EPID device and PF software can be confidently 
used in clinical routine to detect dosimetric, geometrical and 
anatomical discrepancies. The possibility of this in vivo 
evaluation and the potentiality of this new system have a 
very positive impact on improving daily patient QA .  
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Purpose or Objective: The aim of this work is to evaluate 
the perturbed DVHs generated from Tomotherapy dose 
distributions according to the dose discrepancies detected 
with pre-treatment measurements. Through perturbed DVHs 
data, sensitivity and specificity of gamma passing rate (%GP) 
were calculated to evaluate if Gamma Index (GI) metric 
correctly differentiates the high dose error plans from low 
dose error plans. In the literature GI was found to be a poor 
predictor of dosimetric accuracy with planar and volumetric 
dosimeters for IMRT and VMAT techniques, we evaluate if this 
lack of prediction of GI method is valid also for Tomotherapy 
plans. 
 
Material and Methods: 12 patients for prostate cancer (P), 
and 12 for head and neck (HN) cancer, were enrolled in the 
study. All the treatments were delivered using the Helical 
Tomotherapy Hi-ART system (Accuray, Inc., Sunnyvale, CA). 
Pre-treatment QA measurements were performed by using 
the diode array ArcCHECKTM and perturbed DVHs were 
obtained with the 3DVH software (both by Sun Nuclear 
Corporation, Melbourne, FL). Measured and calculated dose 
distributions were compared using the global and local GI 
method with 2%/2 mm, and 3%/3 mm criteria. Low-dose 
thresholds (TH) of 10% and 30% were applied and analyzed. 
Percentage dose differences between DVHs, obtained by TPS 
and by 3DVH were calculated. A %GP equal to 95% and a 
mean absolute DVH 3% dose error were used as thresholds to 
calculate sensitivity and specificity. In order to quantify the 
sensitivity and specificity of GI method, we calculated the 
number of false negative (high Tomotherapy QA passing rates 
indicate large errors in anatomy dose metrics), true positive 
(low Tomotherapy QA passing rates do imply large errors in 
anatomy dose metrics), true negative (high Tomotherapy QA 
passing rates did imply small errors in anatomy dose metrics) 
and false positive (low Tomotherapy QA passing rates did 
imply small errors in anatomy dose metrics). 
 
Results: We found the higher sensitivity (0.55) for global 
normalization with 3%/3mm and TH=30% and the higher 
specificity (0.67) with 3%/3mm for global normalization, both 
for TH 10% and 30%. Instead we obtained the poorer 
sensitivity (0) with 2%/2mm, local normalization, and TH=10% 
because the threshold of 95% is too high for 2%/2mm and 
local normalization. We observed the poorer specificity 
(0.39) for 3%/3mm, local normalization, both for TH=10% and 
30%. For global normalization, 3%/3mm sensitivity and 
specificity were always higher than those of 2%/2mm 
criterion. 
 
Conclusion: The low sensitivity and specificity values of GI 
method, for all the applied criteria, show that the gamma 
index metric have disputable predictive power for per-
patient Tomotherapy QA. 
 
EP-1588  
A methodology for deriving clinically indicative gamma 
index acceptance criteria 
M. Hussein
1Royal Surrey County Hospital, Medical Physics, Guildford, 
United Kingdom 
1, A. Nisbet1, C.H. Clark1 
 
Purpose or Objective: The gamma index (γ) is a common 
method for comparing measured and predicted dose 
distributions. The percentage of points passing with γ<1 (Γ) is 
the most frequently reported analysis metric. However, the 
use of Γ has been reported to have weak correlation against 
clinically relevant metrics and the result also varies 
depending on the Quality Assurance (QA) system 
configuration and software used. Other metrics could be 
extracted from the γ map but have not been rigorously 
evaluated in the literature to address appropriate acceptance 
values. This study has developed a methodology to evaluate 
the suitability of the mean, median, maximum, or near-
maximum γ metrics (γmean, γmedian, γmax, γ1%) and their 
acceptance criteria. 
 
Material and Methods: Investigations were performed using 
simulated data with deliberate changes created in a virtual 
phantom test. The changes included: dose deviations of -5% 
to 5% in 1% steps; and MLC offsets of 1–5mm in 1mm steps. An 
in-house Matlab-based software was used to perform γ 
analysis to extract different metrics. The primary PTV mean 
(PTVmean) and organ at risk maximum (OARmax) dose 
deviations were extracted from the changed plans. The γ 
metrics were correlated against PTVmean and OARmax for 
global γ passing criteria of 3%/2mm (20% threshold relative to 
a point in high dose low gradient). Acceptance criteria 
needed to predict a dose deviation >±3%, for 3%/2mm, were 
assessed using Receiver Operator Characteristic (ROC) 
analysis and assuming 100% sensitivity. The area under the 
ROC curve (AUC) was assessed for each γ metric to assess 
statistical reliability. Since the γ calculation can give varying 
results between different QA systems, the robustness of the 
proposed methodology was tested by varying γ passing 
criteria as well calculating in 2D planes and 3D volumes. 
 
Results: The γmean, γmedian and γ1% metrics had the 
strongest Pearson correlation coefficient (ρ) against the 
PTVmean (ρ>0.95, p<0.01); (Fig. 1). The Γ had a weaker 
correlation of ρ=-0.76. These metrics had ROC AUC>0.9 
(p<0.01) showing statistically strong accuracy for predicting a 
PTVmean deviation >±3% for 3%/2mm. Optimal acceptance 
criteria for achieving 100% sensitivity are shown in Table 1. 
The γmax had the best correlation against OARmax (ρ> 0.8, 
p<0.01) and the AUC was >0.9 and showed that points with 
γ>1.1 may be associated with a >3% increase in the OARmax. 
Correlations between different γ passing criteria were 
statistically strong at >0.95 (p<0.01) as were correlations 
between 2D & 3D γ calculations, indicating the robustness of 
the methodology to the variability in γ calculation that could 
be caused by QA system configuration and software 
implementation. 
 
